Michelle Ross v. Pfizer, Inc.

375 F. App'x 450
CourtCourt of Appeals for the Sixth Circuit
DecidedMarch 23, 2010
Docket09-5526
StatusUnpublished
Cited by11 cases

This text of 375 F. App'x 450 (Michelle Ross v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Michelle Ross v. Pfizer, Inc., 375 F. App'x 450 (6th Cir. 2010).

Opinion

BOYCE F. MARTIN, JR., Circuit Judge.

Michelle Ross, an African-American former employee in Pfizer Inc.’s Corporate Accounting and Analysis Department in Memphis, Tennessee, sued Pfizer for racial discrimination when it promoted a Caucasian employee to a supervisory position instead of Ross. She also claimed constructive discharge, essentially alleging that Pfizer’s failure to promote her and the resulting workplace environment left her no choice but to leave her job for a new, comparably paying job. Finally, she sought compensation for emotional distress. The district court granted summary judgment for Pfizer on all claims, and Ross appeals. We AFFIRM.

I.

Ross began working in Pfizer’s Corporate Accounting and Analysis Department as a staff accountant in 2000, and she was promoted to senior staff accountant in 2005. The Department was responsible for compiling financial and accounting information for Pfizer and forwarding it to the New York office, which handled all public SEC filings. The Department itself was not responsible for any public filings.

The Department was comprised of four divisions; Ross worked in the employee benefits accounting division. Each division had its own supervisor, and each supervisor managed a team of staff and senior staff accountants. At some point in 2005, Monica Morgan became the manager of the entire Department. Thus, the chain of command as of 2005 was that Ross, a senior staff accountant, reported to the supervisor of the benefits division, who in turn reported to Morgan.

In May 2006, one of the supervisors was promoted, so Pfizer posted an advertisement for the open supervisor position. The posting for the position listed as pre *452 ferred qualifications, among other things, “three-plus years of big 4 public accounting (audit)” experience and “previous supervisory experience.” Morgan was responsible for drafting the job posting. She testified that she thought that “big 4 firm” experience, meaning work in the audit division of PricewaterhouseCoopers, Deloitte Touche Tohmatsu, Ernst & Young, or KPMG, was important because it gave an individual exposure to the overall balance sheet of large public companies like Pfizer and because a broad exposure to balance sheet accounting would be useful background for the person filling the open supervisor position.

Ross submitted her resume for the position. She had prior supervisory experience as she had been an interim supervisor for a period of months. However, she did not have experience with a big 4 accounting firm. Ross was chosen for an initial interview, along with four other candidates. At least one of the other candidates, Angela French, was an African-American female with big 4 accounting experience, though hers was not audit experience.

The initial interviews were conducted by Morgan and three of the division supervisors. Ross asserts that at some point during the interview, Morgan said “two people would go on to the second round, and that she was not going to let this monkey be on her back.” Ross asserts that she took the “monkey” reference to be directed at her as an African-American, derived from the “porch monkey” racial slur. Morgan, however, testified that she was using “monkey” in the sense of the common phrase “get this monkey off my back” in reference to a difficult project that she and Ross were working on, signifying that she was putting that project aside to focus on Ross’s interview.

After the first round of interviews, the three supervisors provided Morgan with their recommendations on which two candidates should make it to the next round. Based on this input and her own opinions, Morgan selected two Caucasian women with prior big 4 audit experience to go on to the next round. Morgan eventually chose Amy Shackleford for the supervisor position.

Ross was informed that she did not make it to the second round of interviews on May 25, 2006. That same day, Ross contacted headhunters to begin searching for a new job. Soon after, Morgan became aware that Ross was disappointed at not having been selected. She met, with Ross several times to give feedback on the interview and to discuss how Ross could position herself for the next open position, including giving Ross more leadership opportunities. Pfizer’s Human Resource Director, Dan Brown, also met with Ross. They discussed ways for Ross to get more exposure to auditing and other developmental opportunities, including attending leadership conferences at Pfizer’s expense.

Nevertheless, Ross left Pfizer in July 2006 to take a position at a comparable salary with another large company. In May of 2007, she filed suit alleging claims under Title VII and 42 U.S.C. § 1981 for failure to promote due to racial discrimination, as well as a claim of constructive discharge. During discovery, a dispute arose regarding Ross’s request for documents and information regarding Pfizer’s promotion of one of the supervisors to a position in the New York office. A central aspect of Ross’s attack on Pfizer’s decision not to promote her is the big 4 public audit experience preference, which she claims was unnecessary for a supervisor in the Memphis-based Department and was thus a pretext for a decision not to promote based on her race. Apparently, Pfizer had *453 in 2008 promoted one of the Memphis supervisors, a Caucasian male without public accounting experience, to the New York office, which does engage in public filings and reporting. She claimed that information regarding this promotion was relevant to show that the preference for big 4 accounting experience for a supervisor position in Memphis was unreasonable if Pfizer did not consider such experience necessary for promotion to a position that actually handled public reporting. Pfizer objected to this line of discovery, and the magistrate judge denied Ross’s motion to compel production of this evidence. The district court affirmed the magistrate judge’s decision.

The court eventually granted summary judgment to Pfizer on all claims, finding that Ross had failed to present sufficient evidence to create a question of fact as to whether Pfizer’s proffered reason for not promoting Ross was a pretext and that Ross had not established evidence to support her claim for constructive discharge. Ross timely appealed.

II.

On appeal, Ross takes issue with the court’s grant of summary judgment on her failure to promote and constructive discharge claims, as well as with the discovery ruling. We review the district court’s summary judgment decision de novo. Smith Wholesale Co., Inc. v. R.J. Reynolds Tobacco, Inc., 477 F.3d 854, 861 (6th Cir.2007). Summary judgment is appropriate when “the pleadings, the discovery and disclosure materials on file, and any affidavits show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c)(2). The “mere existence of some alleged factual dispute will not defeat an otherwise properly supported motion for summary judgment; the requirement is that there be no genuine issue of material fact.” Anderson v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

City of Haltom City, Texas v. Nickolas Forrest
Court of Appeals of Texas, 2021
Pittington v. Great Smoky Mountain Lumberjack Feud, LLC
213 F. Supp. 3d 951 (E.D. Tennessee, 2016)
Nolen v. Fedex Techconnect, Inc.
971 F. Supp. 2d 694 (W.D. Tennessee, 2013)
Washington v. Afify
968 F. Supp. 2d 532 (W.D. New York, 2013)
Bryant v. Rolling Hills Hospital, LLC
836 F. Supp. 2d 591 (M.D. Tennessee, 2011)
Jividen v. University of Tennessee
834 F. Supp. 2d 745 (W.D. Tennessee, 2011)
Moore v. Abbott Laboratories
780 F. Supp. 2d 600 (S.D. Ohio, 2011)
Ross v. Pfizer, Inc.
178 L. Ed. 2d 371 (Supreme Court, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
375 F. App'x 450, Counsel Stack Legal Research, https://law.counselstack.com/opinion/michelle-ross-v-pfizer-inc-ca6-2010.